The American College of Rheumatology/Association of Rheumatology Professionals (ACR/ARP) annual meeting took place on November 8th – 13th in Atlanta, Georgia. The conference featured a robust educational program, with over 450 sessions, 3,000 abstracts, and 15,000 participants from around the globe.
The ACR conference included significant updates and sessions on innovative medicine that have the potential to affect the management of rheumatic diseases within Canada. Investigational JAK inhibitors and other oral small molecules, as well as IL-23 inhibitors were prominently featured.
Select members of the CARE™ Rheumatology Faculty used the 2019 ACR conference as an opportunity to meet and discuss the impact of, and continued support for access to innovation and biosimilar adoption, specifically from a Canadian context/perspective.